Ondrej Vanek

Dr. Ondrej Vanek

Department of Biochemistry, Faculty of Science, Charles University
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2015 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
GLGeoffrey M Lynn
Geoffrey M Lynn
RLRichard Laga
Richard Laga
PDPatricia A Darrah
Patricia A Darrah
AIAndrew S Ishizuka
Andrew S Ishizuka
ABAlexandra J Balaci
Alexandra J Balaci
RSRobert Seder
Robert Seder
Vaccine efficacy is enhanced by optimizing the design of polymeric particles for adjuvant and antigen delivery. The efficacy of vaccine adjuvants such as Toll-like receptor agonists (TLRa) can be improved through formulation and delivery approaches. Here, we attached small molecule TLR-7/8a to polymer scaffolds (polymer–TLR-7/8a) and evaluated how different physicochemical properties of the TLR-7/8a and polymer carrier influenced the location, magnitude and duration of innate immune activation in vivo. Particle formation by polymer–TLR-7/8a was the most important factor for restricting adjuvant distribution and prolonging activity in draining lymph nodes. The improved pharmacokinetic profile by particulate polymer–TLR-7/8a was also associated with reduced morbidity and enhanced vaccine immunogenicity for inducing antibodies and T cell immunity. We extended these findings to the development of a modular approach in which protein antigens are site-specifically linked to temperature-responsive polymer–TLR-7/8a adjuvants that self-assemble into immunogenic particles at physiologic temperatures in vivo. Our findings provide a chemical and structural basis for optimizing adjuvant design to elicit broad-based antibody and T cell responses with protein antigens.

1 October 2013 in Journal of Proteomics
Verified
Journal Article
Closed access
HRHelena Ryšlavá
Helena Ryšlavá
VDVeronika Doubnerová
Veronika Doubnerová
DKDaniel Kavan
Daniel Kavan
Ondrej VanekOndrej Vanek
Ondrej Vanek

1 December 2014 in Journal of Environmental Management
Verified
Journal Article
Closed access
ZMZuzana Michálková
Zuzana Michálková
Michael KomárekMichael Komárek
Michael Komárek
HŠHana Šillerová
Hana Šillerová
LPLoïc Della Puppa
Loïc Della Puppa
EJEmmanuel Joussein
Emmanuel Joussein
Vojtěch  EttlerVojtěch Ettler
Vojtěch Ettler

1 June 2021 in Journal of Molecular Biology
Verified
Journal Article
Closed access
YPYoav Peleg
Yoav Peleg
RVRenaud Vincentelli
Renaud Vincentelli
BCBrett M. Collins
Brett M. Collins
KCKai-En Chen
Kai-En Chen
ELEmma K. Livingstone
Emma K. Livingstone
SFSarel Fleishman
Sarel Fleishman

13 October 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
Stepan StehlikStepan Stehlik
Stepan Stehlik
MVMarián Varga
Marián Varga
PŠPavla Štenclová
Pavla Štenclová
LOLukáš Ondič
Lukáš Ondič
MLMartin Ledinsky
Martin Ledinsky
BRBohuslav Rezek
Bohuslav Rezek
Color centers in diamonds have shown excellent potential for applications in quantum information processing, photonics, and biology. Here we report chemical vapor deposition (CVD) growth of nanocrystalline diamond (NCD) films as thin as 5–6 nm with photoluminescence (PL) from silicon-vacancy (SiV) centers at 739 nm. Instead of conventional 4–6 nm detonation nanodiamonds (DNDs), we prepared and employed hydrogenated 2 nm DNDs (zeta potential = +36 mV) to form extremely dense (∼1.3 × 1013 cm–2), thin (2 ± 1 nm), and smooth (RMS roughness < 0.8 nm) nucleation layers on an Si/SiOx substrate, which enabled the CVD growth of such ultrathin NCD films in two different and complementary microwave (MW) CVD systems: (i) focused MW plasma with an ellipsoidal cavity resonator and (ii) pulsed MW plasma with a linear antenna arrangement. Analytical ultracentrifuge, infrared and Raman spectroscopies, atomic force microscopy, and scanning electron microscopy are used for detailed characterization of the 2 nm H-DNDs and the nucleation layer as well as the ultrathin NCD films. We also demonstrate on/off switching of the SiV center PL in the NCD films thinner than 10 nm, which is achieved by changing their surface chemistry.

1 June 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
MAMarko Anderluh
Marko Anderluh
FBFrancesco Berti
Francesco Berti
ABAnna Bzducha‐Wróbel
Anna Bzducha‐Wróbel
FCFabrizio Chiodo
Fabrizio Chiodo
CCCinzia Colombo
Cinzia Colombo
Sandra J. Van VlietSandra J. Van Vliet
Sandra J. Van Vliet
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen‐specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T‐cell immunity in the fight against cancer. The recent SARS‐CoV‐2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan‐coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor‐associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T‐cell‐independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.